SG11202105163UA - Agent for inhibiting iron uptake into cells - Google Patents

Agent for inhibiting iron uptake into cells

Info

Publication number
SG11202105163UA
SG11202105163UA SG11202105163UA SG11202105163UA SG11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA SG 11202105163U A SG11202105163U A SG 11202105163UA
Authority
SG
Singapore
Prior art keywords
cells
agent
iron uptake
inhibiting iron
inhibiting
Prior art date
Application number
SG11202105163UA
Inventor
Lilin Zhang
Fumiko Nomura
Keiko Katsumi
Romi KOTAKA
Yuta OHIRA
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Publication of SG11202105163UA publication Critical patent/SG11202105163UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202105163UA 2018-11-20 2019-11-19 Agent for inhibiting iron uptake into cells SG11202105163UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018217548 2018-11-20
JP2019167013 2019-09-13
PCT/JP2019/045227 WO2020105621A1 (en) 2018-11-20 2019-11-19 Inhibitor of cellular iron uptake

Publications (1)

Publication Number Publication Date
SG11202105163UA true SG11202105163UA (en) 2021-06-29

Family

ID=70774551

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105163UA SG11202105163UA (en) 2018-11-20 2019-11-19 Agent for inhibiting iron uptake into cells

Country Status (12)

Country Link
US (1) US20220332838A1 (en)
EP (1) EP3884959A4 (en)
JP (1) JP7410051B2 (en)
KR (1) KR20210093974A (en)
CN (1) CN113164594A (en)
AU (1) AU2019384781A1 (en)
BR (1) BR112021009768A2 (en)
CA (1) CA3120548A1 (en)
MX (1) MX2021005913A (en)
SG (1) SG11202105163UA (en)
WO (1) WO2020105621A1 (en)
ZA (1) ZA202103554B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116472282A (en) 2020-10-08 2023-07-21 国立大学法人东海国立大学机构 Method for determining efficacy or sensitivity of anti-transferrin receptor antibody
CN117836003A (en) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 ROS (reactive oxygen species) production enhancer
WO2024121755A1 (en) * 2022-12-05 2024-06-13 Sanofi Transferrin receptor binding proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (en) 1992-02-18 2001-11-15 Otsuka Kagaku Kk BETA-LACTAM AND CEPHAM COMPOUNDS AND THEIR PRODUCTION
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (en) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル Recombinant binding proteins and peptides
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US7976841B2 (en) 2004-04-30 2011-07-12 Institut National De La Sante Et De La Recherche Anti TfR antibody
CN101245107B (en) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 Antihuman transferrin acceptor human source antibody and uses thereof
US20100093871A1 (en) * 2007-03-20 2010-04-15 Meiji Seika Kaisha, Ltd. Agent for prevention or treatment of iron overload disorders
WO2011007208A1 (en) * 2009-07-16 2011-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and methods for the treatment of cancer
US9598496B2 (en) * 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JP5939855B2 (en) * 2012-03-23 2016-06-22 国立大学法人 宮崎大学 Transferrin receptor antibody
JP2015524816A (en) * 2012-08-02 2015-08-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Use of transferrin receptor antagonists to treat thalassemia
JP2014093958A (en) * 2012-11-08 2014-05-22 Univ Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
HUE039920T2 (en) * 2012-11-08 2019-02-28 Univ Miyazaki Antibody capable of specifically recognizing transferrin receptor
JP6993228B2 (en) 2014-11-19 2022-03-03 ジェネンテック, インコーポレイテッド Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage
MY187033A (en) * 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
JP2018024615A (en) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Pharmaceutical composition for treating inflammatory disease related to htlv-1

Also Published As

Publication number Publication date
US20220332838A1 (en) 2022-10-20
WO2020105621A1 (en) 2020-05-28
KR20210093974A (en) 2021-07-28
AU2019384781A1 (en) 2021-06-10
JPWO2020105621A1 (en) 2021-10-07
EP3884959A1 (en) 2021-09-29
ZA202103554B (en) 2023-01-25
CA3120548A1 (en) 2020-05-28
EP3884959A4 (en) 2022-08-10
MX2021005913A (en) 2021-06-30
CN113164594A (en) 2021-07-23
BR112021009768A2 (en) 2021-10-19
JP7410051B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
IL275263A (en) Compositions and methods for inhibiting t cell exhaustion
IL272643A (en) Binding agents
GB201802201D0 (en) Binding agents
IL272838B1 (en) Inhibiting ubiquitin specific peptidase 30
ZA202103554B (en) Agent for inhibiting iron uptake into cells
GB201804800D0 (en) Compositions for providing agents that degrade in water
ZA202001283B (en) Iron complex compounds for therapeutic use
IL268288A (en) Binding agents
PL3765646T3 (en) Steel composition
GB201706116D0 (en) Iron ore pellets
ZA202110908B (en) Improved fertiliser
GB2541102B (en) Extension piece for drain hoppers
IL276914A (en) Csf1r binding agents
GB201913756D0 (en) Contrast agent
GB201711208D0 (en) Ion channel inhibitors
EP4071294C0 (en) Cord-winding iron
IL279709A (en) Ask1 inhibiting agents
IL291366A (en) Radiolabelled grpr-antagonist for use as theragnostic
ZA202103578B (en) Dna-cutting agent
ZA202103582B (en) Dna-cutting agent
RS62891B1 (en) Composition for treating constipation
ZA201905047B (en) Briquettes
RO133937B1 (en) Kinetic bench
HK1259489A1 (en) Proenzyme composition
GB201817450D0 (en) Battery composition